Search research articles
Contact Us
Filters
Showing results (101-110 of 148) with videos related to
Page
of 15
Sort By:
Mayo Clinic Proceedings
|
August 6, 2019
Etiologies of Extreme Thrombocytosis: A Contemporary Series
Ronan W Hsieh, Aishwarya Ravindran, Christopher C Hook, et al.
Cancer
|
December 22, 2022
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia
Talha Badar, Mark R Litzow, Rory M Shallis, et al.
American Journal of Hematology
|
February 18, 2026
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent
Naseema Gangat, Momna Warraich, Sudhesh Kumar, et al.
American Journal of Hematology
|
January 28, 2025
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
Ayalew Tefferi, Maymona Abdelmagid, Giuseppe G Loscocco, et al.
Hematological Oncology
|
August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome
Christopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Haematologica
|
May 21, 2026
Insights into clonal and complete blood count changes at disease evolution among patients with clonal cytopenia of undetermined significance
Yazan Jabban, Rong He, Kurt Bessonen, et al.
Haematologica
|
July 9, 2026
Characteristics of clonal cytopenia of undetermined significance in the presence of <i>ZRSR2</i> mutations
Mahmoud Yacout, Bahga Katamesh, Yazan Jabban, et al.
Haematologica
|
July 17, 2025
Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment
Oudai Alkabbani, Yazan Jabban, Rong He, et al.
Ejhaem
|
December 17, 2025
Blast Clearance Dynamics and Time to Response Across <i>IDH1-</i> and <i>IDH2</i>-Mutated AML
Mohamad Sheikh Najeeb, Oudai Alkabbani, Rong He, et al.
American Journal of Hematology
|
June 15, 2022
A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy
Ayalew Tefferi, Naseema Gangat, Aref Al-Kali, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 148) with videos related to
Sort By:
Page
of 15
Mayo Clinic Proceedings
|
August 6, 2019
Etiologies of Extreme Thrombocytosis: A Contemporary Series
Ronan W Hsieh, Aishwarya Ravindran, Christopher C Hook, et al.
Cancer
|
December 22, 2022
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia
Talha Badar, Mark R Litzow, Rory M Shallis, et al.
American Journal of Hematology
|
February 18, 2026
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent
Naseema Gangat, Momna Warraich, Sudhesh Kumar, et al.
American Journal of Hematology
|
January 28, 2025
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
Ayalew Tefferi, Maymona Abdelmagid, Giuseppe G Loscocco, et al.
Hematological Oncology
|
August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome
Christopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Haematologica
|
May 21, 2026
Insights into clonal and complete blood count changes at disease evolution among patients with clonal cytopenia of undetermined significance
Yazan Jabban, Rong He, Kurt Bessonen, et al.
Haematologica
|
July 9, 2026
Characteristics of clonal cytopenia of undetermined significance in the presence of <i>ZRSR2</i> mutations
Mahmoud Yacout, Bahga Katamesh, Yazan Jabban, et al.
Haematologica
|
July 17, 2025
Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment
Oudai Alkabbani, Yazan Jabban, Rong He, et al.
Ejhaem
|
December 17, 2025
Blast Clearance Dynamics and Time to Response Across <i>IDH1-</i> and <i>IDH2</i>-Mutated AML
Mohamad Sheikh Najeeb, Oudai Alkabbani, Rong He, et al.
American Journal of Hematology
|
June 15, 2022
A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy
Ayalew Tefferi, Naseema Gangat, Aref Al-Kali, et al.
Page
of 15